Breast Cancer Is Only Pharmaceutical Pipeline with over 1000 Drugs in Development
The breast cancer treatment pipeline's exceptional levels of activity and innovation, with a staggering 1,050 drugs in active development across all stages and 347 first-in-class programs, may significantly alter the clinical and commercial landscape of the disease market over the next decade, according to business intelligence provider Publisher.
View full press release